GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Large Growth in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) was the recipient of a significant increase in short interest during the month of August. As of August 15th, there was short interest totalling 623,300 shares, an increase of 240.4% from the July 31st total of 183,100 shares. Based on an average daily trading volume, of 6,760,000 shares, the short-interest ratio is currently 0.1 days. Currently, 11.9% of the shares of the company are sold short.

Analysts Set New Price Targets

A number of brokerages recently commented on GOVX. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a research report on Monday, August 12th. Roth Mkm initiated coverage on GeoVax Labs in a research report on Tuesday, July 16th. They issued a “buy” rating and a $20.00 target price on the stock. EF Hutton Acquisition Co. I upgraded GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 23rd. Roth Capital upgraded GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. Finally, Noble Financial upped their price objective on GeoVax Labs from $6.00 to $10.00 and gave the stock an “outperform” rating in a research report on Monday, August 19th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs currently has an average rating of “Buy” and a consensus target price of $12.67.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in GeoVax Labs stock. Armistice Capital LLC purchased a new position in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned about 91.38% of GeoVax Labs at the end of the most recent quarter. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Trading Down 5.2 %

GeoVax Labs stock traded down $0.26 during mid-day trading on Thursday, hitting $4.74. The company had a trading volume of 1,787,625 shares, compared to its average volume of 2,717,342. The company’s fifty day moving average is $3.31 and its 200-day moving average is $2.37. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.57) by $0.58. The business had revenue of $0.30 million for the quarter. During the same period last year, the firm posted ($3.30) earnings per share. Analysts anticipate that GeoVax Labs will post -7.41 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.